Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb CofiledCriticalBristol Myers Squibb Co
Publication of AR121633A1publicationCriticalpatent/AR121633A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
Esta divulgación proporciona anticuerpos aislados que se unen específicamente al receptor de quimiocina 8 del motivo C-C (CCR8) expresado en la superficie de una célula y median el agotamiento de la célula que expresa CCR8 por citotoxicidad celular dependiente de anticuerpos (ADCC). La divulgación proporciona métodos para tratar un sujeto que padece un cáncer que comprenden administrar al sujeto una cantidad terapéuticamente eficaz de un anticuerpo anti-CCR8 como monoterapia o en combinación con un agente anticanceroso tal como un inhibidor del punto de control inmune, por ejemplo, un anticuerpo anti-CCR8, -PD-1 o anti-PD-L1.This disclosure provides isolated antibodies that specifically bind to the C-C motif chemokine receptor 8 (CCR8) expressed on the surface of a cell and mediate depletion of the CCR8-expressing cell by antibody-dependent cellular cytotoxicity (ADCC). The disclosure provides methods of treating a subject suffering from cancer comprising administering to the subject a therapeutically effective amount of an anti-CCR8 antibody as monotherapy or in combination with an anticancer agent such as an immune checkpoint inhibitor, eg, a anti-CCR8, -PD-1 or anti-PD-L1 antibody.
ARP210100710A2020-03-232021-03-22
ANTI-CCR8 ANTIBODIES FOR THE TREATMENT OF CANCER
AR121633A1
(en)
Antibody or antibody fragment against humanized antibody cd38, conjugated to the antibody with a cytotoxic compound pharmaceutical composition with said antibodies using antibodies to treat cancer or autoimmune disease method to diagnose cancer polynucleotide vector and host cell.
Isolated antibody or antigen binding fragment thereof that specifically binds interleukin-25 hjumana (il-2525); pharmaceutical composition comprising it; use of said pharmaceutical composition to treat a disease or disorder associated with the activity or expression of il-25. (divisional application 201700703)